JP2009520697A5 - - Google Patents

Download PDF

Info

Publication number
JP2009520697A5
JP2009520697A5 JP2008546038A JP2008546038A JP2009520697A5 JP 2009520697 A5 JP2009520697 A5 JP 2009520697A5 JP 2008546038 A JP2008546038 A JP 2008546038A JP 2008546038 A JP2008546038 A JP 2008546038A JP 2009520697 A5 JP2009520697 A5 JP 2009520697A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
phosphate
composition according
complex
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008546038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2006/001997 external-priority patent/WO2007070981A1/en
Publication of JP2009520697A publication Critical patent/JP2009520697A/ja
Publication of JP2009520697A5 publication Critical patent/JP2009520697A5/ja
Pending legal-status Critical Current

Links

JP2008546038A 2005-12-23 2006-12-22 サイトカイン調節性を有する化合物 Pending JP2009520697A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005907306A AU2005907306A0 (en) 2005-12-23 Formulations having cytokine regulating properties
AU2006901179A AU2006901179A0 (en) 2006-03-08 Formulations having cytokine regulating properties
PCT/AU2006/001997 WO2007070981A1 (en) 2005-12-23 2006-12-22 Compounds having cytokine modulating properties

Publications (2)

Publication Number Publication Date
JP2009520697A JP2009520697A (ja) 2009-05-28
JP2009520697A5 true JP2009520697A5 (enExample) 2010-02-18

Family

ID=38188188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008546038A Pending JP2009520697A (ja) 2005-12-23 2006-12-22 サイトカイン調節性を有する化合物

Country Status (9)

Country Link
US (1) US20090005348A1 (enExample)
EP (1) EP1973547A1 (enExample)
JP (1) JP2009520697A (enExample)
KR (1) KR20080085839A (enExample)
BR (1) BRPI0621081A2 (enExample)
CA (1) CA2631653A1 (enExample)
IL (1) IL191880A0 (enExample)
RU (1) RU2008123556A (enExample)
WO (1) WO2007070981A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
MXPA04000654A (es) 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
WO2006012692A1 (en) * 2004-08-03 2006-02-09 Vital Health Sciences Pty Ltd Carrier for enteral administration
RU2428973C2 (ru) * 2005-03-03 2011-09-20 Вайтал Хэлф Сайнсис Пти Лтд Составы, обладающие липидопонижающими свойствами
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) * 2011-03-15 2012-09-20 Phosphagenics Limited New composition
MX365403B (es) 2012-01-09 2019-05-31 Serpin Pharma Llc Peptidos y metodos para usarlos.
US20150251407A1 (en) * 2014-03-05 2015-09-10 Heath Moore Painting mask with specialized indicia
AU2016317726B2 (en) * 2015-08-28 2022-05-26 Serpin Pharma, Llc Methods for treatment of diseases
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US20200060311A1 (en) 2016-12-09 2020-02-27 Avecho Biotechnology Limited A method for improving performance parameters of an animal
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
JP6870847B2 (ja) * 2017-04-12 2021-05-12 日本メナード化粧品株式会社 Ｉｌ−８及びｇｍ−ｃｓｆ発現抑制剤
WO2022082256A1 (en) 2020-10-19 2022-04-28 Avecho Biotechnology Limited Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids
WO2022082257A1 (en) 2020-10-19 2022-04-28 Avecho Biotechnology Limited Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2022155656A1 (en) 2021-01-13 2022-07-21 Rodan & Fields, Llc Cosmetic compositions

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407823A (en) * 1946-09-17 Antihemorrhagic esters and methods
US2667479A (en) * 1951-01-30 1954-01-26 Merck & Co Inc Benzimidazole phosphate
US2913477A (en) * 1957-03-22 1959-11-17 Merck & Co Inc Antihemorrhagic compounds and processes for preparing the same
US3127434A (en) * 1959-10-20 1964-03-31 Hoffmann La Roche Dihydrovitamin k monophosphate compounds and preparation thereof
US3212901A (en) * 1961-06-07 1965-10-19 Eastman Kodak Co Stabilized tocopherol concentrates and process for preparing the same
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4141938A (en) * 1976-10-07 1979-02-27 Hoechst Aktiengesellschaft Production of acid orthophosphoric acid ester mixtures
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4299906A (en) * 1979-06-01 1981-11-10 American Hoechst Corporation Light-sensitive color proofing film with surfactant in a light-sensitive coating
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
CH661438A5 (it) * 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
DE3702766A1 (de) * 1987-01-30 1988-08-11 Henkel Kgaa Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern
JP3070744B2 (ja) * 1987-04-10 2000-07-31 株式会社日立製作所 ベクトル処理装置
US4952495A (en) * 1987-06-08 1990-08-28 Eastman Kodak Company Hydrolyzable compounds which release electron transfer agents and analytical use of same
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
IT1236843B (it) * 1989-11-22 1993-04-21 Simes Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati
US5374645A (en) * 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
FR2679904A1 (fr) * 1991-08-01 1993-02-05 Lvmh Rech Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues.
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US5282312A (en) * 1991-12-31 1994-02-01 Tessera, Inc. Multi-layer circuit construction methods with customization features
US5741518A (en) * 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
TW252918B (enExample) * 1993-03-31 1995-08-01 Senju Pharma Co
US5807542A (en) * 1993-11-27 1998-09-15 Knoll Aktiengesellschaft Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
US5554781A (en) * 1994-03-30 1996-09-10 Reierson; Robert L. Monoalkyl phosphonic acid ester production process
TW287103B (enExample) * 1994-04-22 1996-10-01 Senju Pharma Co
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
CA2152693A1 (en) * 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
FR2730928B1 (fr) * 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
US5607968A (en) * 1995-06-07 1997-03-04 Avon Products, Inc. Topical alkyl-2-O-L-ascorbyl-phosphates
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
FR2741263B1 (fr) * 1995-11-22 1997-12-26 Oreal Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5885595A (en) * 1996-05-13 1999-03-23 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic composition with a retinol fatty acid ester
CA2209690A1 (en) * 1996-07-31 1998-01-31 Sachiko Matsuura Therapeutic drug for acne vulgaris
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
CA2282513C (en) * 1997-03-13 2007-09-18 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
DE19824983C2 (de) * 1997-06-04 2001-06-28 Pacific Corp 2-(3-Aminopropylphosphorsäure)-L-ascorbat, Verfahren zu seiner Herstellung und dieses enthaltende kosmetische Zubereitung zur Aufhellung der Haut
US5928631A (en) * 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
US6096326A (en) * 1997-08-15 2000-08-01 Scandinavian-American Import/Export Corporation Skin care compositions and use
US6461623B2 (en) * 1998-04-13 2002-10-08 Kao Corporation Cosmetic composition
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
JP2002519366A (ja) * 1998-07-07 2002-07-02 トランスダーマル・テクノロジーズ・インコーポレーテツド 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
WO2000027402A1 (fr) * 1998-11-06 2000-05-18 Senju Pharmaceutical Co., Ltd. Remedes destines a une administration topique pour lutter contre des maladies allergiques du type iv
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
AUPQ037499A0 (en) * 1999-05-14 1999-06-10 Swig Pty Ltd Improved process for phosphorylation and compounds produced by this method
AUPP829399A0 (en) * 1999-01-25 1999-02-18 Swig Pty Ltd Recovery for chroman derivatives
US6184247B1 (en) * 1999-05-21 2001-02-06 Amway Corporation Method of increasing cell renewal rate
US6423742B1 (en) * 1999-09-02 2002-07-23 Drake Larson Compositions for reducing vascular plaque formation and methods of using same
CA2385989A1 (en) * 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
US6635253B2 (en) * 2000-02-29 2003-10-21 Showa Denko Kabushiki Kaisha Composition for enhancing immunological effects
AU2001236001A1 (en) * 2000-02-29 2001-09-12 Showa Denko K.K. Immune enhancement compositions and use thereof
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
US6444220B2 (en) * 2000-03-16 2002-09-03 Teresa S. Wiley Method and compositions for changing the contour of skin
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6485950B1 (en) * 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
JP4818500B2 (ja) * 2000-09-05 2011-11-16 株式会社ペンタプラストア トコトリエノール誘導体及びその製造方法
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US20020131994A1 (en) * 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
AU2002951045A0 (en) * 2002-08-27 2002-09-12 Vital Health Sciences Pty Ltd Method of supplementing nascent endogenous storage forms
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040067890A1 (en) * 2002-10-04 2004-04-08 Gupta Shyam K. Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
US7033998B2 (en) * 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
AU2003901812A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphates of secondary alcohols
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы

Similar Documents

Publication Publication Date Title
RU2008123556A (ru) Составы, имеющие цитокин модулирующие свойства
JP2005510535A5 (enExample)
RU2010137395A (ru) Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза
CA2516188A1 (en) Chitosan-derivatives for gene delivery and expression
CN1917883A (zh) 曲前列环素改善肾功能的用途
JP2005527496A5 (enExample)
TW200924741A (en) Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells
JP2015524423A5 (enExample)
CA3177338A1 (en) Method for treating respiratory viral infections comprising administration of fatty acid compositions
JP2022524754A (ja) 癌を処置するためにｉＲＧＤと共投与される低用量サイトカイン
EP2903608B1 (en) Pharmaceutical composition comprising propionic acid for use in the treatment of viral infections
JP2005525784A5 (enExample)
JP2021521102A5 (enExample)
TWI233357B (en) Oromucosal cytokine compositions and uses thereof
Vidard et al. Specific T-cell tolerance may reflect selective activation of lymphokine synthesis.
KR20020062349A (ko) 싸이클로펜텐온 유도체
Ohya et al. Ability of orally administered IFN-α-containing transgenic potato extracts to inhibit Listeria monocytogenes infection
Veldhuis et al. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
JP2008505082A5 (enExample)
JP2007509876A (ja) ペラルゴニウム種からの抽出物の使用
JP4414494B2 (ja) 白血球減少症の予防剤および治療剤
Rodenas et al. Cyclic neutropenia: a cause of recurrent aphthous stomatitis not to be missed
CN1535724A (zh) 重组人干扰素用于预防严重性急性呼吸道综合征的新用途
WO2004032918A1 (en) Treatment of inflammatory conditions with ∝-3 polyunsaturated fatty acids
US20240307341A1 (en) Treatment of COVID-19 and Associated Pathologies